Dalteparin did not reduce the incidence of the primary composite outcome in both intention-to-treat analysis ( dalteparin 25/146 [ 171 % ; 95 % CI 114-242 % ] vs no dalteparin 27/143 [ 189 % ; 95 % CI 128-263 % ] ; risk difference -18 % [ 95 % CI -106 % to 71 % ) ) and on-treatment analysis ( dalteparin 28/143 [ 196 % ] vs no dalteparin 24/141 [ 170 % ] ; risk difference +26 % [ 95 % CI -64 to 116 % ] ) .